‘Dangling’ Cancer Indications In US: New Year Brings New Withdrawals Of Accelerated Approvals

 
• By Sue Sutter

Gilead pulls Zydelig’s third-line indications in follicular B-cell lymphoma and small lymphocytic lymphoma due to confirmatory trial enrollment challenges resulting from an evolving treatment landscape; 13 cancer indications now have been withdrawn since the FDA began cracking down on accelerated approvals that have not confirmed clinical benefit.

Jenga block removal
FDA scrutiny has led to removal of accelerated approval cancer indications. • Source: Alamy

More from Clinical Trials

More from R&D